285 related articles for article (PubMed ID: 24651717)
1. Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms.
Ara A; Love RP; Chelico L
PLoS Pathog; 2014 Mar; 10(3):e1004024. PubMed ID: 24651717
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of Enhanced HIV Restriction by Virion Coencapsidated Cytidine Deaminases APOBEC3F and APOBEC3G.
Ara A; Love RP; Follack TB; Ahmed KA; Adolph MB; Chelico L
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881650
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
Feng Y; Love RP; Chelico L
J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
[TBL] [Abstract][Full Text] [Related]
4. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
Refsland EW; Hultquist JF; Harris RS
PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
[TBL] [Abstract][Full Text] [Related]
5. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
Armitage AE; Deforche K; Welch JJ; Van Laethem K; Camacho R; Rambaut A; Iversen AK
J Virol; 2014 Nov; 88(21):12882-94. PubMed ID: 25165112
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of the cytidine deaminase APOBEC3F have different HIV-1 restriction efficiencies.
Mohammadzadeh N; Follack TB; Love RP; Stewart K; Sanche S; Chelico L
Virology; 2019 Jan; 527():21-31. PubMed ID: 30448640
[TBL] [Abstract][Full Text] [Related]
7. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
Holmes RK; Koning FA; Bishop KN; Malim MH
J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
[TBL] [Abstract][Full Text] [Related]
8. Quantification of deaminase activity-dependent and -independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation.
Kobayashi T; Koizumi Y; Takeuchi JS; Misawa N; Kimura Y; Morita S; Aihara K; Koyanagi Y; Iwami S; Sato K
J Virol; 2014 May; 88(10):5881-7. PubMed ID: 24623435
[TBL] [Abstract][Full Text] [Related]
9. Different interaction between HIV-1 Vif and its cellular target proteins APOBEC3G/APOBEC3F.
Nagao T; Yamashita T; Miyake A; Uchiyama T; Nomaguchi M; Adachi A
J Med Invest; 2010 Feb; 57(1-2):89-94. PubMed ID: 20299747
[TBL] [Abstract][Full Text] [Related]
10. Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.
Albin JS; Brown WL; Harris RS
Virology; 2014 Feb; 450-451():49-54. PubMed ID: 24503066
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of the gene-inactivating potential of retroviral restriction factors APOBEC3F and APOBEC3G.
Bélanger K; Langlois MA
J Gen Virol; 2015 Sep; 96(9):2878-2887. PubMed ID: 26048885
[TBL] [Abstract][Full Text] [Related]
12. Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.
Wang X; Dolan PT; Dang Y; Zheng YH
J Biol Chem; 2007 Jan; 282(3):1585-94. PubMed ID: 17142455
[TBL] [Abstract][Full Text] [Related]
13. Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity.
Vetter ML; Johnson ME; Antons AK; Unutmaz D; D'Aquila RT
PLoS Pathog; 2009 Feb; 5(2):e1000292. PubMed ID: 19197360
[TBL] [Abstract][Full Text] [Related]
14. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
15. APOBEC3 Host Restriction Factors of HIV-1 Can Change the Template Switching Frequency of Reverse Transcriptase.
Adolph MB; Ara A; Chelico L
J Mol Biol; 2019 Mar; 431(7):1339-1352. PubMed ID: 30797859
[TBL] [Abstract][Full Text] [Related]
16. Suppression of APOBEC3-mediated restriction of HIV-1 by Vif.
Feng Y; Baig TT; Love RP; Chelico L
Front Microbiol; 2014; 5():450. PubMed ID: 25206352
[TBL] [Abstract][Full Text] [Related]
17. Identification of a critical T(Q/D/E)x5ADx2(I/L) motif from primate lentivirus Vif proteins that regulate APOBEC3G and APOBEC3F neutralizing activity.
Dang Y; Wang X; York IA; Zheng YH
J Virol; 2010 Sep; 84(17):8561-70. PubMed ID: 20592083
[TBL] [Abstract][Full Text] [Related]
18. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
Liddament MT; Brown WL; Schumacher AJ; Harris RS
Curr Biol; 2004 Aug; 14(15):1385-91. PubMed ID: 15296757
[TBL] [Abstract][Full Text] [Related]
19. Biochemical analysis of hypermutation by the deoxycytidine deaminase APOBEC3A.
Love RP; Xu H; Chelico L
J Biol Chem; 2012 Aug; 287(36):30812-22. PubMed ID: 22822074
[TBL] [Abstract][Full Text] [Related]
20. Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain.
Feng Y; Chelico L
J Biol Chem; 2011 Apr; 286(13):11415-26. PubMed ID: 21300806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
